Myelodysplastic syndrome (mds) drugs market to reach $5.56 billion by 2030 at 8.7% cagr, driven by increasing incidences of myeloid leukemia and rising research and development activities.
Read MoreMelanoma drugs market to reach $17.07 billion by 2030 at 11.1% CAGR, driven by increase in the incidence of melanoma in males.
Read MoreMyc proto oncogene protein market to reach $3.44 billion by 2030 at 12.6% cagr, driven by increasing number of clinical trials and rising prevalence of cancer globally.
Read MoreMeganuclease genome editing market to reach $2.69 billion by 2030 at 16.9% CAGR, driven by increasing prevalence of genetic diseases.
Read MoreMedulloblastoma drug market to reach $4.49 billion by 2030 at 8.2% CAGR, driven by rising incidence of brain tumors, increasing healthcare expenditure, and growing focus on personalized medicine.
Read MoreMutation detection kits in genome editing market to reach $2.1 billion by 2030 at 13.0% cagr, driven by rising prevalence of genetic disorders and need for precise genomic analysis.
Read MoreMeditation software market to reach $7.65 billion by 2030 at 11.2% CAGR, driven by growing awareness about stress-related issues.
Read MoreMuscle relaxant drugs market to reach $7.43 billion by 2030 at 7.8% cagr, driven by increasing number of sports injuries and rising cases of musculoskeletal disorders.
Read MoreThe global medicinal mushroom market to reach $66.63 billion by 2030 at 9.6% CAGR, driven by growing vegan population.
Read MoreMultivitamin capsules and tablets market to reach $40.6 billion by 2030 at 6.2% cagr, driven by increasing health consciousness among individuals and demand for preventive nutrition.
Read More